AVIR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWAtea Pharmaceuticals Reports Q3 2026 Financial Results and Provides Business Updates

Nov 9, 2026

8-K

NEWAtea Pharmaceuticals Enters into $200 Million Loan and Security Agreement with Hercules Capital

Nov 9, 2026

8-K

Atea Pharmaceuticals Reports Q2 2026 Financial Results and Positive Phase 3 C-BEYOND Trial Results

Aug 12, 2026

8-K

Atea Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 22, 2026

8-K

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

8-K

Atea Pharmaceuticals Reports Q4 and Full Year 2025 Results, Updates on Global HCV Phase 3 Program, and Announces HEV Pipeline Advancement

Mar 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

OFFERING | Shares amount: 12,500,000 | Share price: $24.00 | Offering amount: $300,000,000.00

Oct 30, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2025

S-3

SHELF | ATM | Offering amount: $500,000,000.00 EFFECTIVE

Nov 7, 2024

POS AM

Form POS AM - Post-Effective amendments for registration statement

May 10, 2022

POS AM

Form POS AM - Post-Effective amendments for registration statement

Feb 28, 2022

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Feb 28, 2022

S-3ASR

Up to $200,000,000 Common Stock PROSPECTUS SUPPLEMENT Jefferies November 24, 2021- EFFECTIVE

Nov 24, 2021

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

TANG CAPITAL MANAGEMENT LLC (Filed by)

Oct 6, 2026

Lucidi Bruno (Reporting)

Jun 23, 2026

BERGER FRANKLIN M (Reporting)

Jun 23, 2026

Berman Howard (Reporting)

Jun 23, 2026

DUNCAN BARBARA GAYLE (Reporting)

Jun 23, 2026

Polsky Bruce (Reporting)

Jun 23, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 20, 2024

CORRESP

Form CORRESP - Correspondence

Nov 15, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 14, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 13, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 30, 2020

CORRESP

Form CORRESP - Correspondence

Oct 29, 2020

Atea Pharmaceuticals, Inc. AVIR · SEC Filings